BioGend Therapeutics Co., Ltd. (TPEX:6733)

BioGend Therapeutics Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	149.79	217.9	219.02	330.51	163.64	136.32
Short-Term Investments	700	300	400	393.76	329.76	552.96
Cash & Short-Term Investments	849.79	517.9	619.02	724.27	493.4	689.28
Cash Growth	47.65%	-16.34%	-14.53%	46.79%	-28.42%	34.36%
Accounts Receivable	59.06	58.96	47.36	26.69	11.27	5.05
Other Receivables	31.17	32.18	33.37	30.67	28.25	23.61
Receivables	90.23	91.14	80.72	57.36	39.52	28.66
Inventory	27.56	20.52	15.96	16.55	4.9	9.03
Prepaid Expenses	2.97	6.87	2	3	4.07	7.57
Total Current Assets	970.55	636.43	717.7	801.18	541.89	734.54
Property, Plant & Equipment	38.63	43.11	49.57	56.2	34.01	8.89
Long-Term Investments	7.05	7.65	8.33	20.34	10	-
Goodwill	17.09	17.09	17.09	17.09	17.09	17.09
Other Intangible Assets	53.16	73.26	114.07	151.04	210.95	261.92
Other Long-Term Assets	38.9	37.85	5.94	4.64	7.89	1.42
Total Assets	1,125	815.38	912.7	1,050	821.82	1,024

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	3.12	2.09	4.22	2.16	2.08	0.49
Accrued Expenses	20.4	27.03	22.29	16.57	17.22	14.39
Current Portion of Leases	3.8	3.73	3.59	3.65	3.49	3.94
Other Current Liabilities	2.9	3.31	3.13	23.87	9.07	6.3
Total Current Liabilities	30.21	36.16	33.23	46.25	31.86	25.13
Long-Term Leases	0.96	2.85	5.84	9.44	12.28	0.48
Long-Term Unearned Revenue	-	-	-	2.5	2.5	2.5
Long-Term Deferred Tax Liabilities	14.53	18.73	27.13	35.52	43.92	52.31
Total Liabilities	45.7	57.74	66.19	93.71	90.56	80.42

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	1,343	1,244	1,243	1,231	1,031	1,031
Additional Paid-In Capital	263.47	-	-	-	-	212.85
Retained Earnings	-522.63	-482.93	-398.32	-281.85	-325.52	-353.91
Comprehensive Income & Other	-16.65	-18.54	-26.58	-7.96	-2.38	-2.16
Total Common Equity	1,067	742.09	817.67	940.96	702.86	887.54
Minority Interest	12.33	15.55	28.84	15.81	28.4	55.91
Shareholders' Equity	1,080	757.64	846.51	956.77	731.27	943.45
Total Liabilities & Equity	1,125	815.38	912.7	1,050	821.82	1,024

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	4.76	6.58	9.43	13.09	15.77	4.42
Net Cash (Debt)	845.03	511.33	609.59	711.18	477.64	684.86
Net Cash Growth	48.78%	-16.12%	-14.28%	48.90%	-30.26%	33.49%
Net Cash Per Share	6.75	4.15	4.95	5.91	4.63	6.76
Filing Date Shares Outstanding	134.32	124.36	124.26	123.08	103.08	103.08
Total Common Shares Outstanding	134.32	124.36	124.26	123.08	103.08	103.08
Working Capital	940.34	600.27	684.47	754.93	510.03	709.42
Book Value Per Share	7.95	5.97	6.58	7.65	6.82	8.61
Tangible Book Value	997.09	651.75	686.51	772.83	474.82	608.52
Tangible Book Value Per Share	7.42	5.24	5.52	6.28	4.61	5.90
Machinery	33.26	33.26	31.6	31.19	24.66	24.55
Construction In Progress	-	-	-	37.57	14.91	-
Leasehold Improvements	38.25	38.15	38.15	0.34	0.34	0.34

Data Source: S&P Global Market Intelligence Last updated: Aug 7, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 8, 2026

Data Sources Report a data error